[ALXN] Alexion Pharmaceuticals, Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 28.04 B

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 127.19 Change: 1.34 (1.06%)
Ext. hours: Change: 0 (0%)

chart ALXN

Refresh chart

Strongest Trends Summary For ALXN

ALXN is in the long-term up 2519% in 25 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. It offers Soliris (eculizumab), a therapeutic product to treat paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. The company also conducts Phase IV clinical trials on Soliris for its usage for the treatment of PNH registry, and aHUS for pediatric and adult; and various Phase II clinical trials for its usage for the treatment of PNH pediatric trial, presensitized renal transplant, delayed kidney transplant graft function, hemolytic uremic syndrome, neuromyelitis optica, myasthenia gravis, and cold agglutinin disease. In addition, it develops Asfotase alfa that is under Phase II clinical trial for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1102/1103, which is in Phase I trial for PNH; ALXN 1007, a novel humanized antibody for treating inflammatory disorders; and cPMP that is

Fundamental Ratios
Shares Outstanding224.02 M EPS3.07 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 17.14% Sales Growth - Q/Q0.14% P/E37.13
P/E To EPS Growth P/S12.36 P/BV7.97 Price/Cash Per Share14.56
Price/Free Cash Flow55.69 ROA13.34% ROE16.74% ROI15.36%
Current Ratio4.92 Quick Ratio4.61 Long Term Debt/Equity0.05 Debt Ratio0.17
Gross Margin90.72% Operating Margin33.65% Net Profit Margin25.97% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities5.07 M Cash From Investing Activities-48.42 M Cash From Operating Activities23.03 M Gross Profit584.2 M
Net Profit170.22 M Operating Profit181.08 M Total Assets13.17 B Total Current Assets2.53 B
Total Current Liabilities769.17 M Total Debt3.5 B Total Liabilities4.61 B Total Revenue636.21 M
Technical Data
High 52 week141.3 Low 52 week93.94 Last close130.9 Last change-0.38%
RSI41.11 Average true range3.76 Beta1.14 Volume2.37 M
Simple moving average 20 days-1.22% Simple moving average 50 days-2.32% Simple moving average 200 days5.77%
Performance Data
Performance Week-0.6% Performance Month3.96% Performance Quart1.14% Performance Half10.45%
Performance Year9.39% Performance Year-to-date34.45% Volatility daily1.92% Volatility weekly4.28%
Volatility monthly8.78% Volatility yearly30.41% Relative Volume244.27% Average Volume1.33 M
New High New Low


2019-06-21 11:05:03 | Alexion's sBLA for Ultomiris Gets Priority Review From FDA

2019-06-21 10:01:02 | 3 Big Biotechs Hold Growth Potential in Second Half of 2019

2019-06-20 09:45:01 | The Zacks Analyst Blog Highlights: Amgen, Alexion, Regeneron, Allergan and Savara

2019-06-20 08:15:00 | U.S. FDA Accepts Supplemental Biologics License Application sBLA for ULTOMIRIS® ravulizumab-cwvz under Priority Review for the Treatment of Atypical Hemolytic Uremic Syndrome aHUS

2019-06-19 16:07:08 | Alexion's ALXN Ultomiris Gets Approval in Japan for PNH

2019-06-19 10:29:02 | Biotech Stock Roundup: Amgen Gets FDA Nod for Kanjinti, Regeneron Presents Data

2019-06-19 07:00:00 | Comet launches with $28M to turn Nobel Prize-winning science into drugs

2019-06-18 08:04:24 | See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.

2019-06-18 06:30:00 | ULTOMIRIS® ravulizumab Receives Marketing Authorization from Japan’s Ministry of Health, Labour and Welfare MHLW for the Treatment of Adults with Paroxysmal Nocturnal Hemoglobinuria PNH

2019-06-17 18:17:10 | Alexion's ALXN PNH Drug Ultomiris Shows Long-Term Efficacy

2019-06-17 13:52:12 | Nasdaq Outperforms, Helped By Software, Biotech; Bitcoin Trading Heats Up

2019-06-14 14:18:37 | Is Alexion Pharmaceuticals, Inc.'s NASDAQ:ALXN High P/E Ratio A Problem For Investors?

2019-06-14 06:30:00 | Positive Phase 3 Extension Data for ULTOMIRIS® ravulizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria PNH Presented at European Hematology Association EHA Congress

2019-06-10 08:04:13 | See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.

2019-06-07 13:22:08 | Here’s What Hedge Funds Think About Alexion Pharmaceuticals, Inc. ALXN

2019-06-07 05:19:00 | 7 Stocks Ripe for M&A as Trade War Pushes Market Off Record Highs

2019-06-06 08:45:12 | Is Alexion ALXN a Solid Growth Stock? 3 Reasons to Think " Yes "

2019-06-05 16:13:00 | 10 Stocks to Buy That Could Be Takeover Targets

2019-06-03 06:00:00 | Could this Biotech be the Best Summer Buy

2019-05-30 14:34:07 | Save the Date: 11 Biotech Stocks to Put on Your Radar

2019-05-29 12:34:22 | 2 Reasons to Like This Pharma Stock Right Now

2019-05-29 07:59:11 | 5 Best-Performing Summer Stocks to Add to Your Watch List

2019-05-26 09:00:00 | 3 Big Biotech Stocks That Warren Buffett Might Like

2019-05-25 09:31:01 | Why Is Alexion ALXN Down 6.3% Since Last Earnings Report?

2019-05-23 10:00:00 | 3 Top Biotech Stocks to Buy Right Now

2019-05-23 09:06:00 | Wedbush Securities Senior Vice President of Equity Research Laura Chico, Ph.D. Initiates Coverage on Six Stocks in the Healthcare and BioTech Space - ACER, ACOR, ALNX, BIIB, DOVA and SAGE

2019-05-21 07:46:11 | Alexion ALXN Stock Up 30.7% YTD: Will the Momentum Stay?

2019-05-20 08:45:12 | 3 Reasons Growth Investors Will Love Alexion ALXN

2019-05-19 07:00:00 | Top 5 New Drug Launches of 2019 -- and the Biotech Stocks That Could Win Big

2019-05-16 09:30:01 | ALXN or ALKS: Which Is the Better Value Stock Right Now?

2019-05-13 16:30:00 | Alexion to Present at the UBS Global Healthcare Conference

2019-05-13 16:30:00 | Alexion to Present at the RBC Capital Markets Annual Healthcare Conference

2019-05-13 09:13:01 | Achillion ACHN Reports Wider-Than-Expected Loss in Q1

2019-05-13 04:50:51 | Alexion Pharmaceuticals, Inc. ALXN: Sound Shore Says the Pharmaceutical Company is Driving Innovation

2019-05-09 09:00:01 | What Makes Alexion ALXN a New Buy Stock

2019-05-07 16:57:08 | Biotech ETFs in Focus on String of Q1 Earnings Beats

2019-05-07 08:02:59 | See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.

2019-05-03 06:30:00 | New England Journal of Medicine Publishes Positive Phase 3 PREVENT Data for SOLIRIS® eculizumab in Patients with Neuromyelitis Optica Spectrum Disorder NMOSD

2019-05-02 18:43:44 | Eaton Vance Worldwide Health Sciences Fund Buys 5 New Stocks

2019-05-02 11:18:03 | The Zacks Analyst Blog Highlights: Biogen, Celgene, Incyte, Alexion and Vertex

2019-05-01 11:52:03 | Biotech Stock Roundup: BIIB, VRTX, ALXN Q1 Earnings Top & Other Pipeline Updates

2019-05-01 08:45:12 | Is Alexion ALXN a Solid Growth Stock? 3 Reasons to Think " Yes "

2019-04-30 08:03:39 | See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.

2019-04-27 12:56:38 | Top Biotech Stocks for February 2019

2019-04-27 08:40:12 | Edited Transcript of ALXN earnings conference call or presentation 25-Apr-19 12:00pm GMT

2019-04-26 10:55:00 | Alexion Receives Positive CHMP Opinion for ULTOMIRIS® ravulizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria PNH

2019-04-25 16:05:19 | This Biotech's Newest Drug Could Own The Market In Just 5 Quarters

2019-04-25 15:52:10 | Alexion Pharmaceuticals Inc ALXN Q1 2019 Earnings Call Transcript

2019-04-25 14:00:00 | Alexion Pharmaceuticals Fires on All Cylinders in Q1

2019-04-25 09:31:01 | Alexion ALXN Q1 Earnings Beat Estimates, Guidance Raised